One case of blastic plasmacytoid dendritic cell neoplasm with neuropathic pain as the initial symptom and literature review
-
摘要: 母细胞性浆细胞样树突细胞肿瘤(BPDCN)是一种罕见的高度侵袭性血液系统恶性肿瘤。典型BPDCN常以皮损为首发症状，同时可累及淋巴结、骨髓、中枢神经系统和其他软组织等。该文报道1例以神经痛为首发症状且整个病程中均未出现皮损的不典型BPDCN患者，并通过文献复习讨论本病的诊断及治疗体会。
-
关键词:
- 母细胞性浆细胞样树突细胞肿瘤 /
- 神经系统 /
- 化疗 /
- 造血干细胞移植
Abstract: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematological malignancy. Typical BPDCN usually has skin lesions as the first symptom, and may also involve lymph nodes, bone marrow, central nervous system and other soft tissues. It reported a case of atypical BPDCN with neuropathic pain as the initial symptom and no skin lesions throughout the course of the disease, then discuss the diagnosis and treatment of this disease through literature review. -
-
[1] Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas(agranular CD4+CD56+ hematodermic neoplasms): a review[J]. Am J Clin Pathol, 2005, 123(5): 662-675. doi: 10.1309/GJWNPD8HU5MAJ837
[2] Nguyen CM, Stuart L, Skupsky H, et al. Blastic Plasmacytoid Dendritic Cell Neoplasm in the Pediatric Population: A Case Series and Review of the Literature[J]. Am J Dermatopathol, 2015, 37(12): 924-928.
[3] Zhang X, Sun J, Yang M, et al. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm[J]. Crit Rev Oncol Hematol, 2020, 149: 102928. doi: 10.1016/j.critrevonc.2020.102928
[4] Pileri A, Delfino C, Grandi V, et al. Blastic plasmacytoid dendritic cell neoplasm(BPDCN): the cutaneous sanctuary[J]. G Ital Dermatol Venereol, 2012, 147(6): 603-608.
[5] Xiao W, Chan A, Waarts MR, et al. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia[J]. Blood, 2021, 137(10): 1377-1391. doi: 10.1182/blood.2020007897
[6] Khoury JD. Blastic Plasmacytoid Dendritic Cell Neoplasm[J]. Curr Hematol Malig Rep, 2018, 13(6): 477-483. doi: 10.1007/s11899-018-0489-z
[7] Cota C, Vale E, Viana I, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients[J]. Am J Surg Pathol, 2010, 34(1): 75-87. doi: 10.1097/PAS.0b013e3181c5e26b
[8] Riaz W, Zhang L, Horna P, et al. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy[J]. Cancer Control, 2014, 21(4): 279-289. doi: 10.1177/107327481402100404
[9] Wang S, Wang X, Liu M, et al. Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents[J]. Ann Hematol, 2018, 97(4): 563-572. doi: 10.1007/s00277-018-3259-z
[10] Beird HC, Khan M, Wang F, et al. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm(BPDCN)[J]. Blood Cancer J, 2019, 9(12): 99. doi: 10.1038/s41408-019-0262-0
[11] Leroux D, Mugneret F, Callanan M, et al. CD4(+), CD56(+)DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique[J]. Blood, 2002, 99(11): 4154-4159. doi: 10.1182/blood.V99.11.4154
[12] Fagan RJ, Dingwall AK. COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer[J]. Cancer Lett, 2019, 458: 56-65. doi: 10.1016/j.canlet.2019.05.024
[13] Kaur E, Agrawal R, Sengupta S. Functions of BLM Helicase in Cells: Is It Acting Like a Double-Edged Sword?[J]. Front Genet, 2021, 12: 634789. doi: 10.3389/fgene.2021.634789
[14] Voutsadakis IA. Landscape of BRIP1 molecular lesions in gastrointestinal cancers from published genomic studies[J]. World J Gastroenterol, 2020, 26(11): 1197-1207. doi: 10.3748/wjg.v26.i11.1197
[15] Laribi K, Baugier de Materre A, Sobh M, et al. Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients[J]. Blood Adv, 2020, 4(19): 4838-4848. doi: 10.1182/bloodadvances.2020002474
[16] 何云地, 张曦, 黄瑞昊. 造血干细胞移植治疗非霍奇金淋巴瘤[J]. 临床血液学杂志, 2020, 33(9): 604-608. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXZ202009004.htm
[17] Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study[J]. Haematologica, 2013, 98(2): 239-246. doi: 10.3324/haematol.2012.072645
[18] 李娜, 周阳, 赵晨, 等. 单倍型造血干细胞移植与同胞相合造血干细胞移植治疗慢性粒-单核细胞白血病的疗效比较[J]. 临床血液学杂志, 2022, 35(5): 323-327. http://www.whuhzzs.com/article/doi/10.13201/j.issn.1004-2806.2022.05.005
[19] Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients[J]. Blood, 2014, 124(3): 385-392. doi: 10.1182/blood-2014-04-566737
[20] Economides MP, Rizzieri D, Pemmaraju N. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm(BPDCN)[J]. Curr Hematol Malig Rep, 2019, 14(6): 515-522. doi: 10.1007/s11899-019-00556-2
[21] Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm[J]. N Engl J Med, 2019, 380(17): 1628-1637. doi: 10.1056/NEJMoa1815105
[22] Kovtun Y, Jones GE, Adams S, et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells[J]. Blood Adv, 2018, 2(8): 848-858.
[23] Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia[J]. N Engl J Med, 2018, 378(5): 439-448. doi: 10.1056/NEJMoa1709866
[24] Montero J, Stephansky J, Cai T, et al. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax[J]. Cancer Discov, 2017, 7(2): 156-164. doi: 10.1158/2159-8290.CD-16-0999
[25] Iversen KF, Holdgaard PC, Preiss B, et al. Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report[J]. Haematologica, 2019, 104(9): e432-e433. doi: 10.3324/haematol.2018.214635
-
下载:
图(2)
计量
- 文章访问数: 1094
- PDF下载数: 281
- 施引文献: 0